GlassScriptPhysician profile
Lance Faddis
NPI 1255398400
$5,836.52
in general payments reported to CMS, 2019-2025
36 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $280 · 2021: $891 · 2022: $872 · 2023: $814 · 2024: $708 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $763.59 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $649.56 | 2021-2025 | |
| Lilly USA, LLC | $544.09 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $518.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $436.42 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $317.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $315.22 | 2019-2024 | Belsomra, Verquvo, Steglatro |
| Pfizer INC. | $250.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.83 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $150.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.69 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $142.67 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.62 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $118.72 | 2019-2020 | |
| Astellas Pharma US INC | $116.98 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Faddis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.